贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌的临床观察

目的 观察贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌的临床疗效及不良反应，评价其有效性和安全性。方法 回顾性分析2009年-2011年收治的经病理学确诊的晚期结直肠癌病例42例，其中22例采用贝伐单抗联合FOLFIRI方案治疗（研究组），20例采用单纯FOLFIRI方案治疗（对照组），观察其疗效和不良反应，并进行随访。结果 42例患者均可评价疗效和不良反应。研究组和对照组的客观有效率分别为45.4%，20.0%；中位生存期分别为15.7月，12.0月，差异均具有统计学意义（P＜0.05）；治疗后两组的肿瘤标志物均有所下降，其中仅研究组CEA差异具有统计学意义（P＜0.05）,余均无统计学意义（P＞0.05）。研究组较对照组增加的不良反应主要有高血压、出血等，发生率分别为27.3%、22.7%，但均为Ⅰ～Ⅱ级，经药物治疗后均可控制，不影响化疗的连续性。结论 贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌能够提高疗效，延长生存时间，且患者耐受性较好，具有较好的临床应用前景。

Clinical Study of Bevacizumab Combined with FOLFIRI Regimen in Treatment of Advanced Colorectal Cancer

Objective  To observe and evaluate the clinical efficacy, toxicity and safety of bevacizumab plus FOLFIRI regimen in the treatment of advanced colorectal cancer.Methods  Forty-two advanced colorectal cancer cases were collected from 2009 to 2011 and confirmed by pathology were divided into 2 groups to receive bevacizumab plus FOLFIRI (the study group) and FOLFIRI only treatment (the control group). The efficacy side effects and survival time in twogroups were observed and compared.Results  Forty-two patients were all evaluable for efficacy and adverse reactions.The objective response rateof the study and control group was 45.4% and 20.0% respectively; the median overall survival of two groups was 15.7 and 12.0 months. The difference were all statistically significant (P＜0.05). Aftertreatment, there were three kinds of decreased tumor markers in two groups, and significant difference of CEA level was just identified in study group (P＜0.05). The toxicity related to bevacizumab includes high blood pressure and bleeding,with the incidence of 27.3% and 22.7%, respectively，but all were grade Ⅰ or Ⅱ，they could be controlled after drug treatment,and didn’t affect the continuity of the chemotherapy.Conclusion   Bevacizumab combined with FOLFIRI regimen can improve efficacy in the treatment of advanced colorectal cancer patients, and the adverse effects were well tolerated.